These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28143868)

  • 41. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
    Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
    Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
    Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
    BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer.
    Numao N; Yoshida S; Komai Y; Ishii C; Kagawa M; Kijima T; Yokoyama M; Ishioka J; Matsuoka Y; Koga F; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
    J Urol; 2013 Aug; 190(2):502-8. PubMed ID: 23473904
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PI-RADS score v.2 in predicting malignancy in patients undergoing 5α-reductase inhibitor therapy.
    Forte V; Cavallo AU; Bertolo R; de Soccio V; Sperandio M; Bove P; Ciccariello M
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):150-155. PubMed ID: 32681155
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Developing a Chinese PI-RADS v2-based nomogram for predicting clinically significant prostate cancer in patients with a prior negative biopsy].
    Huang C; Song G; Wang H; Ji GJ; Chen YK; He Q; Zhou LQ
    Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2559-2563. PubMed ID: 30220139
    [No Abstract]   [Full Text] [Related]  

  • 46. A novel nomogram combined PIRADS v2 and neutrophil-to-lymphocyte ratio to predict the risk of clinically significant prostate cancer in men with PSA < 10 ng/ml at first biopsy.
    Sun J; Zhang Z; OuYang J
    Urol Oncol; 2020 May; 38(5):401-409. PubMed ID: 31870724
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Development of a Chinese nomogram based on muti-parametric magnetic resonance for predicting the probability of prostate cancer in patients after initial negative biopsy].
    Huang C; Ji GJ; Song G; Wang H; Chen YK; Zhou LQ
    Zhonghua Yi Xue Za Zhi; 2018 Jan; 98(2):132-135. PubMed ID: 29343039
    [No Abstract]   [Full Text] [Related]  

  • 48. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical usefulness of free PSA in early detection of prostate cancer.
    Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
    Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
    Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
    Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prostate cancer detection at low prostate specific antigen.
    Schröder FH; van der Cruijsen-Koeter I; de Koning HJ; Vis AN; Hoedemaeker RF; Kranse R
    J Urol; 2000 Mar; 163(3):806-12. PubMed ID: 10687982
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prediction of the risk of harboring prostate cancer by a prebiopsy nomogram based on extended biopsy protocol.
    Nicolaiew N; Ploussard G; Chun FK; Xylinas E; Allory Y; Salomon L; de la Taille A
    Urol Int; 2013; 90(3):306-11. PubMed ID: 23295308
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy.
    Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
    Urology; 2004 Dec; 64(6):1165-70. PubMed ID: 15596191
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biparametric prostate MRI and clinical indicators predict clinically significant prostate cancer in men with "gray zone" PSA levels.
    Wei CG; Chen T; Zhang YY; Pan P; Dai GC; Yu HC; Yang S; Jiang Z; Tu J; Lu ZH; Shen JK; Zhao WL
    Eur J Radiol; 2020 Jun; 127():108977. PubMed ID: 32330776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy.
    Elshafei A; Li YH; Hatem A; Moussa AS; Ethan V; Krishnan N; Li J; Jones JS
    Prostate; 2013 Dec; 73(16):1796-802. PubMed ID: 24038200
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less.
    Zlotta AR; Remzi M; Snow PB; Schulman CC; Marberger M; Djavan B
    J Urol; 2003 May; 169(5):1724-8. PubMed ID: 12686818
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml.
    Kumar V; Jagannathan NR; Kumar R; Thulkar S; Gupta SD; Hemal AK; Gupta NP
    NMR Biomed; 2007 Feb; 20(1):11-20. PubMed ID: 16894640
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prostate Imaging Reporting and Data System and Likert Scoring System: Multiparametric MR Imaging Validation Study to Screen Patients for Initial Biopsy.
    Renard-Penna R; Mozer P; Cornud F; Barry-Delongchamps N; Bruguière E; Portalez D; Malavaud B
    Radiology; 2015 May; 275(2):458-68. PubMed ID: 25599415
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL.
    Al-Azab R; Toi A; Lockwood G; Kulkarni GS; Fleshner N
    Urology; 2007 Jan; 69(1):103-7. PubMed ID: 17270628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.